The data, which comes from a phase 2 trial, were presented at the 2025 Tandem Meetings.
Jordyn Sava
Advertisement
Articles by Jordyn Sava
The phase 1/2 study (NCT05062980) has officially opened enrollment for patients with late-stage non-small cell lung cancer, with plans to initiate patient screening.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial
2
Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025
3
Guess the Therapy Answer October 16, 2025
4
Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation
5
